ZYDUSLIFE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 61/100 — Quality 77 · Valuation 37 · Growth 69 · Momentum 52
| Share price | ₹1,149.00 |
| Market cap | ₹92,775 Cr |
| P/E ratio | 18.8 |
| P/B ratio | 3.7 |
| ROE | 18.3% |
| ROCE | 21.7% |
| Dividend yield | 1.19% |
| Book value | ₹251.49 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹27,148 Cr | ₹5,124 Cr | 31.0% |
| 2025 | ₹23,242 Cr | ₹4,673 Cr | 30.0% |
| 2024 | ₹19,547 Cr | ₹3,973 Cr | 28.0% |
| 2023 | ₹17,237 Cr | ₹2,092 Cr | 22.0% |
| 2022 | ₹15,265 Cr | ₹4,618 Cr | 22.0% |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco